Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients
The purpose of this study is to determine whether simvastatin is effective in the treatment of advanced pancreatic cancer patients.
Pancreatic Cancer
DRUG: Gemcitabine+simvastatin|DRUG: Gemcitabine+Placebo
Time to progression, Every 2 cycles until progression
Safety profiles of gemcitabine/simvastatin, Every cycle until progression|Response rate, Every 2 cycles until progression|Duration of response, Every 2 cycles until progression|Overall survival, Every 3 months|Correlative analyses, after completion of accrual
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.